<article><a style="color: #000080;" href="https://www.dealstreetasia.com/tag/qiming-venture-partners/">Qiming Venture Partners</a>-backed clinical-stage biopharmaceutical company Antengene Corporation has raised a $120-million Series B financing round led by <a style="color: #000080;" href="https://www.dealstreetasia.com/tag/boyu-capital/">Boyu Capital</a> and <a style="color: #000080;" href="https://www.dealstreetasia.com/tag/fountainvest-partners/">FountainVest</a>.</article>

<a style="color: #000080;" href="https://www.dealstreetasia.com/tag/qiming-venture-partners/">Qiming Venture Partners</a>-backed clinical-stage biopharmaceutical company Antengene Corporation has raised a $120-million Series B financing round led by <a style="color: #000080;" href="https://www.dealstreetasia.com/tag/boyu-capital/">Boyu Capital</a> and <a style="color: #000080;" href="https://www.dealstreetasia.com/tag/fountainvest-partners/">FountainVest</a>.
US-based Celgene Corporation, WuXi Corporate Venture Fund, financial services group Taikang and existing investors Qiming Venture Partners and TF Capital also participated in the round.
Antengene had raised a $21-million Series A round in 2017 led by Qiming Venture Partners.
The China-headquartered firm focuses on the development and commercialisation of novel therapeutics for diseases with high unmet medical needs in China and the Asia-Pacific region.
Antengene said the fresh funding will be primarily used for the continuing development of the company&#8217;s selinexor and inhibitor projects and other clinical-stage assets, to expand its pipeline through internal R&amp;D and external partnerships, and to prepare the commercial launch of late-stage drug candidates.
A nearly 170,000-square feet manufacturing and research facility in Shaoxing, China, is currently under construction for GMP manufacturing and will provide both the clinical and commercial drug supply for the company&#8217;s pipeline products.
Boyu Capital, the lead investor of the transaction, has previously backed other Chinese biopharmaceutical firms such as Curon Biopharma and Brii Biosciences.
“We view in-licensing of first-in-class/best-in-class drug candidates as an effective solution to the unmet clinical needs in China. In addition, we are very impressed with the progress that Antengene is making and the pipeline they are building,” commented Yanling Cao, managing director of the Hong Kong-based private equity firm.
Zhen Li, managing director of FountainVest, added: &#8220;In the coming decade, China will rapidly fill the gap in healthcare compared to Western countries. This trend will continuously bring opportunities to innovative biopharmaceutical companies such as Antengene. But it also requires patient capital and financial investor with strategic angle. That&#8217;s how FountainVest position ourselves.&#8221;
Also Read:
<a href="https://www.dealstreetasia.com/stories/sequoia-yunfeng-brii-biosciences-98500/">Sequoia, Yunfeng back $260m round in healthcare startup Brii Biosciences</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/gic-china-cstone-97520/">Singapore’s GIC leads $260m Series B round in Chinese biopharma firm CStone</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/wuxi-healthcare-ventures-leads-55m-series-investment-lifemine-therapeutics-82611/">China’s Wuxi Healthcare Ventures leads $55m Series A in US-based LifeMine Therapeutics</a>
<a style="color: #ff0000;" href="https://www.dealstreetasia.com/stories/temasek-curon-biopharma-103711/">Temasek backs $150m Series A in Chinese startup Curon Biopharma</a>

The round was led by Boyu Capital and FountainVest, and joined by Celgene, WuXi Corporate Venture Fund, Taikang and existing investors Qiming and TF Capital.

Qiming-backed biopharma firm Antengene raises $120m Series B round

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Qiming-backed biopharma firm Antengene raises $120m Series B round

Start your deal-making journey now!

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief